Pro Medicus (PME) Stock Price, News & Analysis

Company Overview

Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers Visage radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 285,954 shs
• Average Volume: N/A
• Market Capitalization: $29.16 billion
• P/E Ratio: 351.99
• Dividend Yield: 0.14%
• Price Target: N/A
• Consensus Rating: N/A

PME Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Pro Medicus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pro Medicus investors own include Mineral Resources (MIN), ResMed (RMD), Technology One (TNE), ARB (ARB), Accent Group (AX1), Cochlear (COH) and CSL (CSL).

Company Calendar

• Ex-Dividend for 3/20 Dividend: 2/26/2025
• Today: 3/12/2025
• Dividend Payable: 3/20/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: ASX:PME
• CIK: N/A
• Web: www.promed.com.au
• Phone: 61 3 9429 8800
• Fax: N/A
• Employees: 2,060
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A$0.78
• Trailing P/E Ratio: 351.99
• Forward P/E Ratio: N/A
• P/E Growth: 3.87
• Net Income: $82.79 million
• Net Margins: 51.27%
• Pretax Margin: N/A
• Return on Equity: 47.73%
• Return on Assets: 30.68%

Debt

• Debt-to-Equity Ratio: 1.10
• Current Ratio: 5.98
• Quick Ratio: 4.39

Sales & Book Value

• Annual Sales: $161.50 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 71.76
• Book Value: A$1.80 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 104,500,000
• Free Float: N/A
• Market Cap: $29.16 billion
• Optionable: Not Optionable
• Beta: 0.56